Erythropoietin, progenitor cells and restenosis. A critique of Stein et al.

Thromb Haemost 2012; 107(06): 1193
DOI: 10.1160/TH12-02-0114

Author Correspondence

Schattauer GmbH

Authors

Tetsuo Minamino

¹Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Niigata, Japan
Ken Toba

²First Department of Internal Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Shuichiro Higo

¹Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Niigata, Japan
Daisaku Nakatani

¹Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Niigata, Japan
Takuya Ozawa

²First Department of Internal Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan

References
1 Stein A, Mohr F, Laux M. et al. Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. Thromb Haemost 2012; 107: 769-774.
2 Ott I, Schulz S, Mehilli J. et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-413.
3 Ozawa T, Toba K, Suzuki H. et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction – randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010; 74: 1415-1423.
4 Taniguchi N, Nakamura T, Sawada T. et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010; 74: 2365-2371.
5 Voors AA, Belonje AM, Zijlstra F. et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-2600.
6 Opie LH. Erythropoietin as a cardioprotective agent: down but not out. Heart 2011; 97: 1537-1539.